GeneditBio接受FDA的人类试验GEB-101, GEB-101是一种基因组编辑疗法,治疗导致视力丧失的罕见眼病。 GenEditBio gets FDA go-ahead for human trials of GEB-101, a genome-editing therapy for a rare eye disease causing vision loss.

GeneditBio已获得美国林业发展局的批准,开始GEB-101临床试验。 GEB-101是其生物基因组编辑疗法,对象是TGFBI 角膜萎缩症,这是一种罕见的遗传性眼病,导致视力丧失。 GenEditBio has received approval from the U.S. FDA to begin clinical trials for GEB-101, its in vivo genome-editing therapy targeting TGFBI corneal dystrophy, a rare genetic eye disorder causing vision loss. 林业发展局对调查性新药(IND)申请的审批使该公司能够开始人体测试,这标志着朝着治疗该病症的可能方向迈出了重要一步。 The FDA’s clearance of the Investigational New Drug (IND) application allows the company to initiate human testing, marking a significant step toward potential treatment for the condition.